Metabolomics-Driven Drug Discovery Platform for Better Medicines
Official title: Development and Validation of Data Standards and Computational Methods for Large Scale Metabolomics Data Analysis for Data Driven Drug Discovery
Funded at Sinopia Biosciences, INC. · NIH-11316610 · Data updated 2026-11-12
A research project aims to create and validate a new metabolomics-based method to help discover and optimize drugs using advanced AI and high-throughput data.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sinopia Biosciences, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | May 1, 2024 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,477,110 |
| NIH project number | 2R44GM154585-02 |
| Project ID | NIH-11316610 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not a patient-facing trial; however, insights from the platform could eventually impact drugs relevant to human diseases.
✕Less likely to help
No direct patient participation is expected in this grant.
What this research studies
This project combines cutting-edge metabolomics with machine learning to analyze how small molecules affect biological systems. Researchers at Sinopia Biosciences and Omix Technologies developed a platform called metD4 to profile thousands of compounds across many proteins, aiming to predict how drugs work and what side effects they might have. They built a neural network-based representation to compare data across experiments, addressing past problems with inconsistent measurements. If successful, the work could streamline drug discovery and improve translation to patients.
Why it matters
Potential benefit: Could lead to faster, more accurate identification of promising drug candidates and better prediction of safety signals.
How similar studies have gone: Preliminary analyses suggest metabolomics can outperform transcriptomics in predicting drug properties, but broader validation is ongoing.
Where this research is happening
-
Sinopia Biosciences, INC.
San Diego, United States Active
Researchers
- Principal investigator: Bloem, Bernard — Sinopia Biosciences, INC.
- Study coordinator: Bloem, Bernard
Related research
Other NIH-funded projects on the same topics.
-
Newborn screening: using gene and metabolite data to refine true vs false positives
A study using genetic and metabolomic data from newborn blood spots to better distinguish real metabolic disorders from false alarms.
-
IDEAL: How early-life immune development shapes vaccine responses and asthma risk
A child-focused project that looks at how the developing immune system in early life affects vaccine responses, respiratory infections, and asthma.
-
Integrative metabolomics to improve sarcoidosis diagnosis and prognosis
A research project from UCLA aims to find blood-based biomarkers that help diagnose sarcoidosis earlier and predict how it will progress, especially in African American women.
-
Metabolomics clues to how ultra-processed foods affect risk of type 2 diabetes
A scientist-led study will look at how eating different ultra-processed foods may change diabetes risk by using a controlled feeding trial and big population data, focusing on adults.
-
Longitudinal metabolomics in infants with food allergies
A study in infants aims to understand how gut metabolites relate to the development of food allergies, including IgE-mediated and non-IgE cases.
-
Biospecimen, Metabolomics, and Pathology Core for Endometrial Cancer Research
A national, multi-institutional resource collects and analyzes tissue, blood, and metabolites from endometrial cancer patients to support multiple research projects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.